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ABSTRACT
Trauma-induced heterotopic ossification (HO) occurs after severemusculoskeletal injuries and burns,
and presents a significant barrier to patient rehabilitation. Interestingly, the incidence of HO signif-
icantly increases with repeated operations and after resection of previous HO. Treatment of estab-
lished heterotopic ossification is challenging because surgical excision is often incomplete, with
evidence of persistent heterotopic bone. As a result, patients may continue to report the signs or
symptoms of HO, including chronic pain, nonhealing wounds, and joint restriction. In this study,
we designed a model of recurrent HO that occurs after surgical excision of mature HO in a mouse
model of hind-limb Achilles’ tendon transection with dorsal burn injury. We first demonstrated that
key signalingmediators ofHO, including bonemorphogenetic protein signaling, are diminished inma-
ture bone. However, upon surgical excision, we have noted upregulation of downstream mediators
of osteogenic differentiation, including pSMAD 1/5. Additionally, surgical excision resulted in re-
emergence of amesenchymal cell populationmarked by expression of platelet-derived growth factor
receptor-a (PDGFRa) and present in the initial developing HO lesion but absent in mature HO. In the
recurrent lesion, these PDGFRa1mesenchymal cells are also highly proliferative, similar to the initial
developingHO lesion. These findings indicate that surgical excisionofHOresults in recurrence through
similar mesenchymal cell populations and signaling mechanisms that are present in the initial devel-
opingHO lesion. These results are consistentwith findings inpatients thatnew foci ofectopic bonecan
develop in excision sites and are likely related to de novo formation rather than extension of unre-
sected bone. STEM CELLS TRANSLATIONAL MEDICINE 2016;5:1–8
SIGNIFICANCE
Secondary operations in common clinical scenarios such as joint replacements, traumatic wounds,
and burn injuries are often complicated by a more robust inflammatory response, fibrosis, and com-
plications such as heterotopic ossification than are primary operations. Heterotopic ossification (HO)
presents a substantial barrier to rehabilitation of patients who have incurred severe trauma. How-
ever, surgical excision of HO is fraught with complications, including the development of recurrent
ectopic bone. In this study, amodel of recurrent HO similar to that seen in secondary procedures was
validated, demonstrating that similar signaling mechanisms and mesenchymal cell populations re-
sponsible for initial HO are present within the recurrent HO lesion. These findings indicate that re-
current HO is not simply an extension of unresected bone but rather represents new heterotopic
bone lesions for which prophylactic measures are likely required.
INTRODUCTION
Trauma-induced heterotopic ossification (HO) is
the pathologic formation of extraskeletal bone
that occurs after severe musculoskeletal injuries
or orthopedic operations such as total hip arthro-
plasty (THA) [1–4]. Interestingly, the incidence of
HO in secondary THAs is nearly four times that of
primary operations. HO insidiously develops in
patients months after the inciting traumatic
event. Patients may complain of chronic pain,
the sensation of a bony prominence, loss of mus-
cle or joint excursion, and even open wounds.
When patients have these signs or symptoms,
plain-film radiographs or computed tomography
(CT) imaging can elucidate the underlying cause.
Currently, therapeutics targetedatHOarebe-
ing investigated for their ability to prevent or
mitigate the key signaling processes involved
in the development of cartilage or subsequent
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ossification of this ectopic cartilage [5–8]. However, patients who
present with the signs or symptoms of HO typically already have
ossified lesions with radiographic opacity (Fig. 1A). As a result,
therapeutics targeting the step-wise development of HO are in-
effective, leaving surgical excision as the only viable option.
Surgical excisionofHO is a challengingundertaking for several
important reasons. First, it is unclear that excision of the offend-
ing bone will restore joint function or range of motion, reduce
chronic pain, or even improve wound healing. Second, HO may
develop near critical structures, including nerves, which pre-
cludes aggressive resection. As a result, HO resection may be in-
complete. Finally, patients who undergo surgical excision have
been noted to develop recurrences in the site of HO [9–11]
(Fig. 1B–1D).
Recurrent HO is particularly difficult to manage because sur-
gical excision is nearly impossible in a wound bed heavily scarred
from the inciting trauma and subsequent initial HO excision. Ad-
ditionally, patients who have undergone joint replacement sur-
gery require aggressive rehabilitation to return to function,
which is further impeded by the recurrent HO. Critical structures,
including nerves or vessels, are difficult to visualize within the
scarred tissue and may be destroyed during excision of recurrent
HO, presenting limb- and even life-threatening risk to the patient.
However, it has been unclear whether HO recurrence is due to de
novo ectopic cartilage forming secondarily to the repeated insult
of surgery.
Wepreviously developed amodel of primary trauma-induced
HO, combining the systemic inflammatory insult of a dorsal skin
burn with severe local connective tissue trauma in the form of an
Achilles tenotomy. Although tenotomy in a mousemodel has the
capacity for limited HO formation, the addition of burn trauma
generates robust and reliable formation of a primary HO lesion
[2, 3]. In this study, we present our experience with a model of
HO recurrence using amodel ofmusculoskeletal trauma followed
by excision andmonitoring viamicroCT and histologic evaluation.
METHODS
Mice
Animal procedures were carried out in accordance with pub-
lished guidelines [12] approved by the Institutional Animal Care
and University Committee on the Use and Care of Animals of the
University of Michigan (UCUCA; approval no. PRO0005909).
Wild-type C57BL/6malemice (age 8–10weeks) were purchased
from Charles River Laboratory (Wilmington, MA, http://www.
criver.com) and used for all experiments. Mice were housed
three per cage at 22°C6 4°C (72°F6 4°F) with 12 hours of light
exposure daily (325 lux), and fed 5L0D chow (Land O’ Lakes, St.
Louis, MO, http://www.labdiet.com).
Burn Injury and Tenotomy Model for Initial
HO Formation
Allmice intended for in vivo development of heterotopic ossifica-
tion underwent 30% total body surface area partial-thickness
burn injury to the dorsum under 3% inhaled isoflurane. A metal
block was heated to 60°C in a water bath and placed over the
shaved dorsum for 18 seconds. After burn injury, mice received
a left hind-limb Achilles tenotomy, using sterile surgical scissors,
and the incisionwas closedwith a single 5-0Vicryl suture. Animals
were housed in UCUCA-supervised facilities, threemice per cage,
receiving 12 hours of light exposure daily, with no restrictions to
diet. All mice were housed in the same facility.
Model of Recurrent HO After Surgical Excision
Themodel of recurrent HOwas performed by excision of HO that
formed in the burn/tenotomy model. Nine weeks after burn/
tenotomy injury, microCT imaging was performed to confirm
presence of HO. The tenotomy site was re-entered using a sterile
scissors, and regions of ectopic bone disjoint from surrounding
bony structures were excised under loupe magnification. Bone
contiguous with the calcaneus was left undisturbed to avoid dis-
ruption of the normal bony cortex. The sitewas then closedwith a
single 5-0 Vicryl suture.
MicroCT Imaging and Analysis
In vivo development of HO was assessed with microCT scans 9
weeks after trauma, immediately before surgical excision
(microCT using 80 kVp, 80 mA, and 1,100 millisecond exposure;
GE Healthcare Biosciences, Pittsburgh, PA, http://www.
gelifesciences.com). A subsequent microCT scan was performed
within 3 days after excision to confirm the site of HO excision. A
final microCT image was obtained 9 weeks after excision to re-
evaluate the site. Images were reconstructed and HO volume
was computed using a calibrated imaging protocol [3]. The voxel
size for all scans was 48.08mmand the field of viewwas 38.47 cm
3 38.47 cm. Scanswere performed from themost distal aspect of
the foot to themid-thigh. The region of interest evaluated for HO
extended from the knee to the foot.
Figure 1. Clinical scenario of recurrent HO in a patient with total hip
arthroplasty. (A): Primary HO in total hip arthroplasty patient (red
square). (B): Postexcision radiograph showing substantial reduction
in HOwith some residual lesions. (C): Early evidence of recurrence af-
ter excision of HO. (D): Recurrent HO lesion 6months after surgery at
excision site. Abbreviation: HO, heterotopic ossification.
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Confirmation of Resection and De Novo HO Recurrence
Pre- andpostsurgicalmicroCTanalysis of theexcision sitewasper-
formed along with a follow-up microCT at 9 weeks postresection
immediately before sacrificing the animal as described earlier in
Methods. These serial CT images were used first to confirm the
absence of residual bone at our resection site and second to guide
further histologic analyses, as explained in detail later in this
article.
Werestrictedourevaluationof recurrentHOto thosedenovo
lesions occurring proximal to our resection site and that (a) did
not have radiologic evidence of residual HO and (b) remained
in discontinuity from any calcaneal remnant HO. We confirmed
this first with CT imaging and then with follow-up hematoxylin
and eosin (H&E) staining of histologic sections to demonstrate
the absence of osseous or cartilaginous tissue bridging any two
distinct HO lesions.
Histology
Animalswere euthanized 3weeks after the initial burn/tenotomy
injury, 9 weeks after burn/tenotomy, or 9 weeks after surgical
excision of HO. The injured hind limb was fixed in 10% formalde-
hyde at 4°C (39°F) for 24 hours, followed by decalcification in
19% EDTA. Specimens were then paraffin embedded and sliced
5-mm thick. Slides were stained with H&E to obtain overall histo-
logic architecture, aniline blue to assess mature osteoid, and saf-
ranin O to assess cartilage extracellular matrix. Immunostaining
was performed using anti- bone morphogenetic protein-2
(BMP2), anti-pSMAD 1/5, anti-collagen IIa (COLIIA), anti-
collagen X (COLX), anti-Ki67, anti-platelet-derived growth factor
receptor-a (PDGFRa), and anti-SOX9 (Santa Cruz Biotechnology,
Santa Cruz, CA, https://www3.scbt.com).
RESULTS
HO Recurred After Excision
Patients who undergo surgery for severe trauma injuries or joint
replacementmayundergo surgical excision to removeHO lesions.
Mature, recurrent HO can be detected within the excisional
wound bed with radiography (Fig. 1A–1D).
Surgical Excision Resulted in HO Recurrence
Upon confirming that key mediators of initial HO development
are absent after 9 weeks, we set out to create a model of HO re-
currence. Therefore, 9 weeks after burn/tenotomy, mice under-
went surgical excision of the identifiable HO lesions. MicroCT
scanswere performed immediately before and immediately after
excision, followed by a subsequent microCT scan 9–12 weeks af-
ter excision (Fig. 2A). We found that the initial HO lesion could be
excised surgically, albeit incompletely, based on pre- and imme-
diate postexcision microCT imaging (Fig. 2B, 2C).
When microCT scans obtained immediately postexcision
and at 9 weeks postexcision were compared, we noted inter-
val increase in the size of the HO lesion, as well as the forma-
tion of distinct de novo osseous lesions occurring separately
from the original site of HO formation (Fig. 2B, 2C). Based
on these findings, we surmised that HO had recurred in and
around the excision site. Histologic evaluation confirmed
the presence of ectopic bone within the recurrent lesions af-
ter excision (Fig. 2D).
Recurrent HO Lesions Showed Osteoid Characteristic of
Early Initial HO Lesions
We set out, therefore, to confirm the presence de novo HO by
using histologic analysis. To characterize the osteoid early after
initial hind-limb injury, tissue slices isolated from mice 3 weeks
after injury were stained with aniline blue (Fig. 3A). These stains
showed minimal evidence of mature osteoid. However, 9 weeks
after burn/tenotomy, the entire heterotopic lesion consisted of
mature osteoid with a developing marrow space. These findings
established the character of osteoid within the initial HO lesion.
Interestingly, when recurrent HO was analyzed 9 weeks after ex-
cision, the recurrent lesions showed regionswith andwithout an-
iline blue stain (Fig. 3A). These findings suggest that recurrent HO
exhibits characteristics of both mature and immature osteoid
when analyzed 9 weeks postexcision.
Recurrent HO Lesions Showed Evidence of Recurrent
BMP Signaling
Bonemorphogenetic protein (BMP) signalinghasbeen implicated
in the developing HO lesion, prompting our interest in whether
this is apparent in the mature HO lesion 9 weeks after injury.
Immunostaining for BMP2 and pSMAD 1/5, a downstreammedi-
ator of BMP signaling, was only minimally present in mature HO,
in contrast with the developing lesion (Fig. 3B, 3C). These findings
suggest that both BMP expression and downstream receptor sig-
naling are substantially diminished in the mature HO lesion.
To demonstrate that recurrent HO lesions re-express the
key signaling mediators present in developing HO, we again
performed immunostaining for BMP2 and pSMAD 1/5. Robust
BMP2 and pSMAD 1/5 expression was observed in the recurrent
HO lesion, consistent with the osteogenic tissue environment
seen during early HO (Fig. 3B, 3C). Taken together, these findings
confirm that recurrent HO lesions express signaling mediators
present during the initial HO development but absent in mature
HO.
Recurrent HO Lesions Showed Evidence of
New Cartilage
Because a substantial amount of the recurrent HO appeared im-
mature, we next evaluated sections for cartilage using safranin
O and COLIIA (Fig. 4A). Early after injury, characteristic safranin
O and COLIIA staining was observed, which is indicative of cartil-
agepresence. This stainingpatternwasno longer present 9weeks
after injury, consistent with the development of mature HO.
However, 9 weeks after excision, new safranin O and COLIIA stain-
ing was observed within the re-excision site. These findings are
indicative of recurrent cartilage extracellular matrix formation
following excision.
Recurrent HO Lesions Underwent De Novo
Endochondral Ossification
To confirm that cartilage present in recurrent lesions undergoes
denovoendochondral ossification,weevaluateddeveloping,ma-
ture, and recurrentHOusingCOLX. COLXexpression in endochon-
dral lesions is restricted to the hypertrophic chondrocytes that
immediately proceed formation of ectopic bone. We found that
COLX-positive hypertrophic chondrocytes were present in both
developing and recurrent HO (Fig. 4B). These cells were absent
in the mature HO, consistent with the completion of endochon-
dral ossification in those tissues (Fig. 4B). We further evaluated
Agarwal, Loder, Cholok et al. 3
www.StemCellsTM.com ©AlphaMed Press 2016
ID: srinivasanv Time: 19:10 I Path: Z:/SCTM/Vol00603/170034/Comp/APPFile/JW-SCTM170034
l , l t l. 801
. ll . Oc 2016 The Authors
STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
the overlap of COLIIA and COLX cells within developing mature
HO and recurrent HO (Fig. 4C, 4D). Although we found no significant
difference in the frequency of COLX-positive chondrocytes (p = .45)
between developing and recurrent lesions, mature lesions were sig-
nificantly depleted of COLX-positive cells (p = .009; Fig. 4D).
Recurrent HO lesions Showed Evidence of Proliferative
Mesenchymal Cells
To confirm a highly proliferative cellular population, immunostain-
ing for Ki67wasperformed (Fig. 5A). Ki671 cellswere absent in the
mature osteoid but present in substantial quantities in both the
developing HO lesion and the recurrent HO. To confirm that
the new cartilage and bone being formed were not derived from
the remaining unresected bone, immunostaining formesenchymal
cell populations was performed using PDGFRa (Fig. 5B). Immunos-
taining showed evidence of robust PDGFRa1 cell presence within
the initial developing HO lesion. These cells were also positive for
CD105 and CD90 (supplemental online Fig. 1). As expected, these
undifferentiated mesenchymal cell populations were absent in
the mature osteoid. However, within recurrent HO, PDGFRa1
re-emerged similar to developing HO.
Recurrent HO Lesions Showed Evidence of De Novo
Chondrogenic Differentiation
To confirm that mesenchymal cells within the recurrent lesion
were actually undergoing chondrogenic differentiation, immu-
nostaining for the chondrogenic transcription factor SOX9 was
performed (Fig. 5C). As expected, SOX91 cells were present
Figure2. RecurrentHO following surgical excision. (A):Experimental design todevelop recurrence. (B):Three-dimensionalmicroCT reconstruc-
tions showing images immediately prior to excision, immediately following excision, and recurrence 9 weeks after excision. Green arrows =
site of de novo recurrent HO; orange arrow = site of HO developing from remnant HO; red arrows = site of original unresected HO; yellow arrow =
region of resected HO. (C): MicroCT cross-sections of HO lesions. Red box = site of unresected HO; yellow box = site of resected HO. (D): H&E
staining showing architecture of early HO 3 weeks after injury, mature HO 9 weeks after injury, and recurrent HO 9 weeks after excision. Green
box = site of HO. Abbreviations: H&E, hematoxylin and eosin; HO, heterotopic ossification; microCT, micro-computed tomography.
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during the early phase of initial HO formation, as well as within
recurrent lesions, which we had previously shown to be both saf-
raninOandCOLIIa positive (Fig. 4). Therewere fewSOX91 cells in
the mature HO 9 weeks after injury (Fig. 5C). We then confirmed
that these cells were indeed PDGFRa/SOX9 double positive via
costaining (Fig. 5D, 5E). Notably, we found no significant differ-
ence in the extent of costaining between the developing primary
and recurrent HO lesion (p = .29; Fig. 5E). Together, these findings
indicate that recurrent HO forms through an endochondral inter-
mediary and is not the result of direct extension from residual,
unresected HO.
DISCUSSION
Trauma-induced HO develops through an insidious process and
typically presentswith signs and symptoms including chronic pain
andbonyprominences, openwounds, and restricted rangeofmo-
tion and muscle excursion [1–4]. When patients show radio-
graphic evidence of HO, the only available recourse is surgical
excision, which is unable to reverse the long-term effects of ec-
topic bone formation, and which often results in recurrence.
However, acute HO and recurrent HO are very different
phenomena from the perspective of patient management.
Whereas the initial HOexcisionmaybenefit froma relatively fresh
wound bed with clear delineation of important structures (e.g.,
nerves or vessels), sites of recurrent HO are heavily scarred due
to the initial trauma compounded by the subsequent excision.
Additionally, recurrent HO can be psychologically difficult for
patients who are already faced with intense rehabilitation
regimens. Surgical re-excision can risk loss of limb or life, or
may again lead to recurrence or incomplete resection. Therefore,
we must identify techniques that minimize the risk for recurrence
in patients who have HO and desire surgical excision. This repre-
sents a highly targeted patient population, primed for postsurgi-
cal prophylactic intervention. In this study, we designed and
validated a model of recurrent trauma-induced HO that recapit-
ulates critical signaling mediators involved in HO formation.
Initially, we found that although HO can recur as an extension
of preexisting and remnant osseous tissue, de novo lesions form
reliably both within the resection site and in adjacent tissues.
These de novo lesions are radiographically and histologically dis-
tinct fromareasofHOarising frompreexistingboneandappear to
undergo the same critical steps of HO formation that led to the
primary lesion.
Figure 3. Osteoid and BMP signaling characteristics of recurrent HO. (A):Aniline blue staining shows presence ofmature osteoid 9weeks after
HO, andemerging anilineblue staining inboth earlyHOanddeveloping recurrentHO lesions. Redarrows= sites of osteoid. (B):BMP2expression
is elevated in the developing HO lesion, reduced in mature osteoid 9 weeks after injury, and recurs in the recurrent HO lesion. (C): pSMAD 1/5
expression is elevated in the developing HO lesion, reduced inmature osteoid 9weeks after injury, and recurs in the recurrent HO lesion.White
arrows = representative sites of positive staining. Scale bar = 200 mm. Abbreviations: BMP2, bone morphogenetic protein-2; HO, heterotopic
ossification.
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In particular, we found that during initial development,
trauma-induced HO sites showed high levels of both BMP2 and
downstream BMP signaling mediators (e.g., pSMAD 1/5). BMP2
and pSMAD 1/5 staining is virtually absent when mature HO
has formed, 9 weeks after the initial injury. However, surgical ex-
cision results in the redevelopment of these signaling factorswith
continued, long-term expression. BMP signaling has previously
been shown to be a mediator of heterotopic ossification, and is
a known contributor to genetic forms of HO as well [5, 13–15].
These findings are consistent with the absence of cartilage on
Safranin O staining when mature HO has formed, followed by
renewed cartilage formation after excision. Heterotopic ossifica-
tion is largely believed tooccur through anendochondral process,
and the identification of cartilage in recurrent lesions confirms
that recurrent HO forms through a similar cartilage intermediary
[16–19]. Overall, these findings provide a mechanistic explana-
tion for observed recurrence.
To exclude the possibility that the recurrence of HO was not
simply interval growth of the previous HO, we performed immu-
nostaining for cellular subtypes surrounding the recurrent ectopic
bone, including chondrocytes (i.e., Sox9) and mesenchymal cells
(i.e., PDGFRa). Both stains demonstrated evidence of cellular
contributions to HO that extend beyond simple osteoid produc-
tion, which would be implied by bone growth. These cell types
are absent in mature HO before excision, suggesting that at least
excision is leading to a resurgence of cell subtypes that eventually
contribute to HO as well. Previous studies have indicated that
PDGFRa1 mesenchymal cells are present in developing hetero-
topic ossification lesions [20–24]. These cells coexpress markers
of chondrogenesis, including Sox9, and are believed to contribute
to the growing ectopic cartilage lesion that eventually ossifies. In
our model of recurrence, we identified these mesenchymal cells
in the site of excision, which provides further evidence that our
model is one of de novo ectopic bone rather than simple exten-
sion of unresected bone. Furthermore, these cells appear to be
highly proliferative, consistent with their role in HO formation
within the excision site.
This model of HO is easily reproducible and can be used by
other researchers studying response to repeated trauma. First,
the burn/tenotomymodel was used to initiate HO formation at
the site of tendon transection. Nineweeks later, thematureHO
lesion was excised using a straight-line vertical incision along
the distal, posterior hind limb. The bone was visible under
loupe magnification and easily removed from the surrounding
soft-tissue structures. Because the initial HO forms predictably
in the burn/tenotomy model, surgical excision can be per-
formed reliably. A critical aspect of this model is that microCT
evaluation should be performed immediately prior to and fol-
lowing surgical excision to ensure that a portion or all of the
bone was successfully excised. In our study, we found that a
substantial amount of heterotopic bone could be excised but
that some remnants of HO remained. However, the over-
whelming presence of new PDGFRa1 cells and new cartilage
formation based on safranin O and Sox9 staining confirmed
that the new ectopic bone seen 9 weeks after excision was
not simply an extension of unresected HO. Rather, it appears
to be derived from mesenchymal cells that re-emerge within
the retraumatized excision site.
Figure 4. New cartilage in recurrent lesions undergoes de novo endochondral ossification. (A): Safranin O and COLIIA staining shows cartilag-
inous extracellular matrix in the developing and recurrent HO lesions, whereas mature HO shows marrow and osteoid with minimal cartilage
presence. (B):Hypertrophic chondrocytes (white arrows) labeled by COLX immunostaining are present in developing HO and recurrent HO, but
relatively diminished in mature HO. (C): Representative image demonstrating the overlap of COLIIA and COLX in hypertrophic chondrocytes
(white arrows) present in areas of cartilage actively undergoing endochondral ossification. (D): Quantification of COLX1 hypertrophic chon-
drocytes in the cartilage anlagen of developing, mature, and recurrent HO. All values are normalized to developing HO. p, p. .05. Error bars
represent standarddeviation. Scale bars =200mm.Abbreviations: COLIIA, collagen II a; COLX, collagenX;HO, heterotopic ossification; HPF, high-
power field.
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To our knowledge, this model appears to be the only one to
demonstrate and validate recurrent heterotopic ossification. The
clinical need for this model is clear based on radiographic evi-
dence of recurrence, which occurs in 10%–15% of patients who
undergo initial excision [25]. In a recent study of outcomes after
surgical excision of HO, 6% of patients who underwent initial ex-
cisionwent on to require re-excision surgery. In the face of a stag-
gering number of patients with combat-related injuries, joint
replacement surgeries, or limb amputations who are at risk for
HO, this represents a large absolute number of patients who
may develop recurrence. Surprisingly, more than half of patients
with radiographic evidence of recurrence were on a regimen
of prophylactic measures consisting of nonsteroidal anti-
inflammatory drugs after excision [25]. These findings point to
a need for improved prophylactic measures are based on an un-
derstanding of the mesenchymal cell populations and signaling
processes involved in recurrence development.
Our findings are encouraging from a therapeutic perspective.
They demonstrate similarities between recurrent HO and initial
HO development. For patients who undergo surgical excision of
HO, it is possible that therapeutics beingevaluated for their ability
to inhibit trauma-induced HO initiation may also be used to
prevent recurrence [6, 7, 26–28]. Prevention of recurrent HO
presents a critical opportunity for physicians caring for patients
postexcision. Although it can be difficult to determine whether
a patient with traumatic injury may develop HO initially, it is easy
to risk stratify patients who have already had HO and have under-
gone surgical excision. Thesepatients are high risk, and treatment
of all patients who have undergone surgical excision may repre-
sent an approach that can efficiently prevent HO.
The future value of this model lies not only with testing of ther-
apeutics to demonstrate prevention of recurrence but also in studies
to determine hownew trauma can lead to bone growth. By identify-
ing the cell subtypes responsible for newbone formation,wemaybe
able to identify cells capable of healing normal bone defects.
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